Epigenetic silencing of CRABP2 and MX1 in head and neck tumors

Neoplasia

Volumn 11, Issue 12, 2009, Pages 1329-1339

  Calmon, Marilia F ^a   Rodrigues, Rodrigo V ^b,c   Kaneto, Carla M ^c   Moura, Ricardo P ^d   Silva, Sabrina D ^e   Mota, Louise Danielle C ^e   Pinheiro, Daniel G ^c   Torres, Cesar ^e   De Carvalho, Alex F ^e   Cury, Patrícia M ^b   Nunes, Fabio D ^c   Nishimoto, Ines Nobuko ^e   Soares, Fernando A ^e   Da Silva, Adriana M A ^f   Kowalski, Luis P ^e   Brentani, Helena ^e   Zanelli, Cleslei F ^a   Silva Jr , Wilson A ^c   Rahal, Paula ^a   Tajara, Eloiza H ^b,c   Carraro, Dirce M ^e   Camargo, Anamaria A ^d   Valentini, Sandro R ^a   more..

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^e A C CAMARGO CANCER CENTER   (Brazil)

^f HOSPITAL HELIÓPOLIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BINDING PROTEIN; BIOLOGICAL MARKER; BISULFITE; CELLULAR RETINOIC ACID BINDING PROTEIN 2; MYXOVIRUS RESISTANCE PROTEIN; MYXOVIRUS RESISTANCE PROTEIN 1; PEPTIDE TRANSPORTER 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DISEASE FREE SURVIVAL; DNA METHYLATION; EPIGENETICS; GENE IDENTIFICATION; GENE SEQUENCE; GENE SILENCING; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; LYMPHOCYTE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SUBTRACTIVE HYBRIDIZATION; SURVIVAL RATE;

EID: 72949092280     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91110     Document Type: Article

References (63)

1. McMahon S and Chen AY (2003). Head and neck cancer. Cancer Metastasis Rev 22, 21-24.
2. Goldenberg D, Lee J, KochWM, KimMM, Trink B, Sidransky D, andMoon CS (2004). Habitual risk factors for head and neck cancer. Otolaryngol Head Neck Surg 131, 986-993.
3. Parkin DM, Bray F, Ferlay J, and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108.
4. Moriniere S (2006). Epidemiology of head and neck cancer [in French]. Rev Prat 56, 1637-1641.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ (2007). Cancer statistics, 2007. CA Cancer J Clin 57, 43-66.
6. Brasil (2007). Estimativa 2008: Incidência de Câncer no Brasil. Rio de Janeiro: Ministério da Saúde. Secretaria de Atenção à Saúde. Brasil: Instituto Nacional do Câncer.
7. Barnes L, Eveson JW, Reichart P, and Sidransky D (2005). World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumors. Lyon, France: IARC Press.
8. Ha PK and Califano JA (2006). Promoter methylation and inactivation of tumoursuppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7, 77-82.
9. Shaw R(2006).The epigenetics of oral cancer. Int J OralMaxillofac Surg 35, 101-108.
10. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, and Kelsey KT (2002). Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21, 4231-4236.
11. CalmonMF,Colombo J,Carvalho F, Souza FP, Filho JF, Fukuyama EE,Camargo AA, Caballero OL, Tajara EH, Cordeiro JA, et al. (2007). Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. Cancer Genet Cytogenet 173, 31-37.
12. Kozaki K, Imoto I, Mogi S, Omura K, and Inazawa J (2008). Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68, 2094-2105.
13. Smith IM, Mydlarz WK, Mithani SK, and Califano JA (2007). DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer 121, 1724-1728.
14. Richards KL, Zhang B, Baggerly KA, Colella S, Lang JC, Schuller DE, and Krahe R (2009). Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS ONE 4, e4941.
15. Costello JF, FruhwaldMC, SmiragliaDJ, Rush LJ,RobertsonGP, Gao X,Wright FA, Feramisco JD, Peltomaki P, Lang JC, et al. (2000). Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24, 132-138.
16. Esteller M (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8, 286-298.
17. Shames DS, Minna JD, and Gazdar AF (2007). Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 251, 187-198.
18. Jones PA and Buckley JD (1990). The role of DNA methylation in cancer. Adv Cancer Res 54, 1-23.
19. Jiang H, Kang DC, Alexandre D, and Fisher PB (2000). RaSH, a rapid subtraction hybridization approach for identifying and cloning differentially expressed genes. Proc Natl Acad Sci USA 97, 12684-12689.
20. Ewing B, Hillier L, Wendl MC, and Green P (1998). Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 8, 175-185.
21. Ewing B and Green P (1998). Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 8, 186-194.
22. Smit AF (1999). Interspersed repeats and other mementos of transposable elements in mammalian genomes. Curr Opin Genet Dev 9, 657-663.
23. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, and Lipman DJ (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25, 3389-3402.
24. Gomes LI, Silva RL, Stolf BS, Cristo EB, Hirata R, Soares FA, Reis LF, Neves EJ, and Carvalho AF (2003). Comparative analysis of amplified and nonamplified RNA for hybridization in cDNA microarray. Anal Biochem 321, 244-251.
25. Maschietto M, de Camargo B, Brentani H, Grundy P, Sredni ST, Torres C, Mota LD, Cunha IW, Patrao DF, Costa CM, et al. (2008). Molecular profiling of isolated histological components of wilms tumor implicates a common role for the Wnt signaling pathway in kidney and tumor development. Oncology 75, 81-91.
26. Vencio RZ and Koide T (2005). HTself: self-self based statistical test for low replication microarray studies. DNA Res 12, 211-214.
27. Gardiner-Garden M and FrommerM(1987). CpG islands in vertebrate genomes. J Mol Biol 196, 261-282.
28. Pfaffl MW (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45.
29. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, and Speleman F (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3; RESEARCH0034.
30. Herman JG,Graff JR,Myohanen S, Nelkin BD, and Baylin SB (1996).Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93, 9821-9826.
31. Liang G, Gonzales FA, Jones PA, Orntoft TF, and Thykjaer T (2002). Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 62, 961-966.
32. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, and Baylin SB (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31, 141-149.
33. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ, and Sidransky D (2002). Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2, 485-495.
34. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, and Goggins M (2003). Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63, 3735-3742.
35. Lodygin D, Epanchintsev A, Menssen A, Diebold J, and Hermeking H (2005). Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65, 4218-4227.
36. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, et al. (2002). Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8, 2246-2252.
37. Haller O, Staeheli P, and Kochs G (2007). Interferon-induced Mx proteins in antiviral host defense. Biochimie 89, 812-818.
38. Holzinger D, Jorns C, Stertz S, Boisson-Dupuis S, Thimme R, Weidmann M, Casanova JL, Haller O, and Kochs G (2007). Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol 81, 7776-7785.
39. Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Muller M, Lengauer T, et al. (2007). Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 6, 14.
40. Desmond JC, Raynaud S, Tung E, Hofmann WK, Haferlach T, and Koeffler HP (2007). Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia 21, 1026-1034.
41. Mibayashi M, Nakad K, and Nagata K (2002). Promoted cell death of cells expressing human MxA by influenza virus infection. Microbiol Immunol 46, 29-36.
42. Astrom A, Tavakkol A, Pettersson U, Cromie M, Elder JT, and Voorhees JJ (1991). Molecular cloning of two human cellular retinoic acid-binding proteins (CRABP). Retinoic acid-induced expression of CRABP-II but not CRABP-I in adult human skin in vivo and in skin fibroblasts in vitro. J Biol Chem 266, 17662-17666.
43. Banaszak L, Winter N, Xu Z, Bernlohr DA, Cowan S, and Jones TA (1994). Lipid-binding proteins: a family of fatty acid and retinoid transport proteins. Adv Protein Chem 45, 89-151.
44. Budhu AS and Noy N (2002). Direct channeling of retinoic acid between cellular retinoic acid-binding protein II and retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acid-induced growth arrest. Mol Cell Biol 22, 2632-2641.
45. De Luca LM (1991). Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. Faseb J 5, 2924-2933.
46. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, et al. (1990). Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323, 795-801.
47. Jetten AM, Kim JS, Sacks PG, Rearick JI, Lotan D, Hong WK, and Lotan R (1990). Inhibition of growth and squamous-cell differentiation markers in cultured human head and neck squamous carcinoma cells by β-all-trans retinoic acid. Int J Cancer 45, 195-202.
48. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, Rosmentz N, Clerici M, Soresi E, Valente M, et al. (1993). Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11, 1216-1222.
49. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, and Peck GL (1988). Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318, 1633-1637.
50. Jing Y, Waxman S, and Mira-y-Lopez R (1997). The cellular retinoic acid binding protein II is a positive regulator of retinoic acid signaling in breast cancer cells. Cancer Res 57, 1668-1672.
51. Chomienne C, Fenaux P, and Degos L (1996). Retinoid differentiation therapy in promyelocytic leukemia. FASEB J 10, 1025-1030.
52. Garattini E, Gianni M, and Terao M (2007). Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr Pharm Des 13, 1375-1400.
53. Schug TT, Berry DC, Shaw NS, Travis SN, and Noy N (2007). Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129, 723-733.
54. Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, and Noy N (2008). Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR. Proc Natl Acad Sci USA 105, 7546-7551.
55. Hu L, Crowe DL, Rheinwald JG, Chambon P, and Gudas LJ (1991). Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res 51, 3972-3981.
56. Zou CP, Clifford JL, Xu XC, Sacks PG, Chambon P, Hong WK, and Lotan R (1994). Modulation by retinoic acid (RA) of squamous cell differentiation, cellular RA-binding proteins, and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. Cancer Res 54, 5479-5487.
57. Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, Hassan K, Feng L, Lee JJ, Lippman SM, et al. (2004). Hypermethylation of the retinoic acid receptor-β(2) gene in head and neck carcinogenesis. Clin Cancer Res 10, 1733-1742.
58. Okuducu AF, Janzen V, Ko Y, Hahne JC, Lu H, Ma ZL, Albers P, Sahin A, Wellmann A, Scheinert P, et al. (2005). Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer. Int J Oncol 27, 1273-1282.
59. Thompson M, Lapointe J, Choi YL, Ong DE, Higgins JP, Brooks JD, and Pollack JR (2008). Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle. Prostate 68, 1248-1256.
60. Uchikado Y, Inoue H, Haraguchi N, Mimori K, Natsugoe S, Okumura H, Aikou T, and Mori M (2006). Gene expression profiling of lymph node metastasis by oligomicroarray analysis using laser microdissection in esophageal squamous cell carcinoma. Int J Oncol 29, 1337-1347.
61. Park JC, Chae YK, Son CH, Kim MS, Lee J, Ostrow K, Sidransky D, Hoque MO, and Moon C (2008). Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun 365, 221-226.
62. Donato LJ and Noy N (2005). Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling. Cancer Res 65, 8193-8199.
63. Donato LJ, Suh JH, and Noy N (2007). Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling. Cancer Res 67, 609-615.